Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
NCT05245903
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer Disease
- Dementia Alzheimers
- Dementia
- Cognitive Impairment
- Mild Cognitive Impairment
- Neurodegenerative Diseases
- Neurocognitive Disorders
- Neurocognitive Dysfunction
- Cognitive Dysfunction
- Mental Disorder
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 89 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Mclean Hospital
- Last updated on ClinicalTrials.gov
- November 6, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- McLean Hospital · Belmont, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.